Gilead Sciences (GILD) Reiterated at Overweight by Cantor Fitzgerald on Yeztugo TRx Gains
April 6, 2026 7:39 AM
Cantor Fitzgerald analyst Carter Gould reiterated an Overweight rating and $155.00 price target on Gilead Sciences (NASDAQ: GILD).The analyst commented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
